Can an IDO/PD-L1 com­bo ever work? No­vo-backed com­pa­ny spells out how in biotech's lat­est IPO fil­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Add an­oth­er biotech to the horde of com­pa­nies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER